Spyre Therapeutics, Inc. SYRE Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -31.1%+34.7pp | -25.2%+34.1pp | -38.1%— | -49.8%— | -65.8%+326pp | |
| Liquidity | ||||||
| Current ratio | 9×+0.9× | 13.3×+2.0× | 10.9×+3.6× | 6.5×-13.2× | 8.1×-3.3× | |
| Per Share | ||||||
| Book value per share | $8.54+6.6% | $11.17+1.4% | $7.53+17.1% | $7.55-8.6% | $8.01+92.0% | |
| Valuation | ||||||
| Market capitalization | $3.96B+307% | $2.54B+82.6% | $1.01B-32.4% | $930.05M-22.1% | $972.25M-29.1% | |
| Price / book | 5.9×+3.9× | 3.6×+0.9× | 2.2×-2.3× | 2×-1.1× | 2×-7.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Spyre Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Spyre Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.